// App-Quantinova.ai

35 : Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL

Researchers

Presenter

  • Joshua J Oaks

Principal Investigators

  • Ramasamy Santhanam

  • Danilo Perrotti

  • Paolo Neviani

  • Jason G Harb

  • Gregory Ferenchak

  • Justin Ellis

  • Guido Marcucci

  • Yosef Landesman

  • Sharon Shacham

  • Michael Kauffman

Medical Centers

  • The Ohio State Univerisity, Columbus, OH

Locations

  • United States

Companies

  • Karyopharm Therapeut

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Annexin V

  • p53

  • Cluster of Differentiation 34

  • Exportin 1

Drug/Treatment

  • Imatinib

  • IkT001

  • L-Tyrosine

  • KPT-330

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved